This outcome not only reaffirmed the synergistic anti-tumor effects of doxorubicin and peposertib observed in vitro, but also highlighted the potential for an improved therapeutic window with the combination of peposertib and PLD, as evidenced in this tumor model. Here, GPLD1 is linked to neoplasm.